Gastroenterology

Gastroenterology

Volume 111, Issue 4, October 1996, Pages 863-870
Gastroenterology

Metabolism of alcohol by human gastric cells: Relation to first-pass metabolism

https://doi.org/10.1016/S0016-5085(96)70054-9Get rights and content

Abstract

BACKGROUND & AIMS: The bioavailability of orally administered alcohol is incomplete, indicating first-pass metabolism. There is debate regarding the site of first-pass metabolism and specifically whether the stomach has the metabolic capacity to account for first-pass metabolism. The aim of this study was to assess ethanol metabolism by human gastric mucosa cells in primary culture. METHODS: Cells were incubated with [1-14C]ethanol, and the quantity of ethanol oxidized was measured by the production of [1-14C]acetate. RESULTS: Gastric cells cultured from men produced 7.3 +/- 3.5 mumol acetate.10(6) cells-1.h-1, which was more than that generated in cells from women (3.2 +/- 0.6; P < 0.05). Acetate production was inhibited by 4-methylpyrazole (a class I alcohol dehydrogenase [ADH] inhibitor) and by m-nitrobenzaldehyde (a selective substrate for class IV ADH isoenzyme) but not by sodium azide (a catalase inhibitor). Cimetidine (a gastric ADH inhibitor) reduced acetate production by as much as 59%, whereas ranitidine had no significant effect. CONCLUSIONS: Human gastric cells metabolize sufficient alcohol to account for the bulk of first-pass metabolism. At least two isozymes of gastric ADH contribute to this metabolism. Cimetidine, but not ranitidine, inhibits gastric alcohol metabolism in keeping with its inhibition of in vivo first-pass metabolism. (Gastroenterology 1996 Oct;111(4):863-70)

References (0)

Cited by (72)

  • Octreotide-based therapies effectively protect mice from acute and chronic gastritis

    2022, European Journal of Pharmacology
    Citation Excerpt :

    In south America and Asia, around half of people are suffering from gastritis and it is brought on by multiple pathogenesis, including non-steroidal anti-inflammatory drugs (NSAIDs), alcohol consumption and Helicobacter pylori (H. pylori) infection (Eshraghian, 2014). It is believed that alcoholism is a common clinical diagnosis of erosive gastritis and alcoholic liver diseases that can generate acute damage to gastric mucosa, making the mucosa vulnerable to gastric acid, various digestive enzymes, bile, etc (Haber, 2000; Haber et al., 1996). In addition, ethanol can increase the expression of gastrin in antrum, thereby promoting gastric acid secretion (Kusterer et al., 1994).

  • Inhibition of human alcohol and aldehyde dehydrogenases by aspirin and salicylate: Assessment of the effects on first-pass metabolism of ethanol

    2015, Biochemical Pharmacology
    Citation Excerpt :

    At 1.5 mM aspirin, the inhibitions of ADH activities were low (<5.1%) except for ADH2 (21%) and ADH1A (65%). Since ethanol concentrations in stomach fluid in a social drinking setting may reach 200 mM or higher [18,40], the inhibition of gastric ADH4 activity at 200 mM ethanol by 1.5 mM aspirin and salicylate were assessed to be 0.26% and 4.0%, respectively. At 10 μM acetaldehyde, 1.5 mM salicylate considerably inhibits activities of ALDH1A1 (71%) and ALDH2 (73%) but the inhibitions by 1.5 mM aspirin are considerably reduced, that is, 9.8% and 27%, respectively.

  • Inhibition of human alcohol and aldehyde dehydrogenases by cimetidine and assessment of its effects on ethanol metabolism

    2013, Chemico-Biological Interactions
    Citation Excerpt :

    Recently cimetidine has been shown to have potential anticancer effects [10]. Chronic use of cimetidine and alcohol are commonly associated, but studies on their interaction and the influences on first-pass and systemic metabolism of ethanol are controversial [1,11–17]. Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) are the principal enzymes responsible for metabolism of ethanol in humans, catalyzing conversion of ethanol to acetaldehyde and then to acetate, respectively [18,19].

  • Alcohol and gastrointestinal tract function

    2013, Bioactive Food as Dietary Interventions for Liver and Gastrointestinal Disease
  • Alcohol and gastrointestinal tract function

    2012, Bioactive Food as Dietary Interventions for Liver and Gastrointestinal Disease: Bioactive Foods in Chronic Disease States
View all citing articles on Scopus
View full text